So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...

Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted and present in the US'.

Pascal Soriot, who runs drugs giant AstraZeneca, has slipped to third place in our annual survey, after being replaced by the ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic.

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

AstraZeneca CFO Aradhana Sarin tells Yahoo Finance the company sees US innovation threatened by China, even as it commits $50 ...

The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the European Union may have not been the ideal ...

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...